Alpha 2.0
Login Register
» Authors » Cristhian Orellana

Cristhian Orellana

Explore the profile of Cristhian Orellana including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 10
Citations 21
Followers 0
Related Specialties
General Surgery
General Medicine
Nephrology
Top 10 Co-Authors
Auxiliadora Mazuecos
Florentino Villanego
Teresa Garcia
Luis Alberto Vigara
Ana Maria Gomez
Javier Naranjo
Juan Manuel Cazorla
Marta Alonso
Veronica Escudero
Santiago Villamayor
Published In
Nefrologia (Engl Ed)
Transplantation
Nefrologia
Front Med (Lausanne)
Clin Transplant
Affiliations
Soon will be listed here.
Recent Articles
1.
Use of glucagon-like peptide type 1 receptor agonists in kidney transplant recipients
Vigara L, Villanego F, Orellana C, Eady M, Sanchez M, Alonso M, et al.
Nefrologia (Engl Ed) . 2024 Dec; 44(6):885-893. PMID: 39645509
Introduction: In kidney transplant (KT) recipients diabetes mellitus (DM) are associated with an increased mortality and a poorer graft survival. Glucagon-like peptide 1 receptor agonists (GLP1-RA) have demonstrated cardiovascular and...
2.
Treatment with PCSK9 inhibitors in patients with chronic kidney disease at very high cardiovascular risk
Amaro J, Villanego F, Naranjo J, Orellana C, Vigara L, Narvaez C, et al.
Nefrologia (Engl Ed) . 2024 Jan; 43 Suppl 2:133-135. PMID: 38296719
No abstract available.
3.
Humoral Response After 5 Successive Doses of COVID-19 Vaccine in Kidney Transplant Patients: Comment
Cazorla J, Villanego F, Aguilera A, Garcia T, Orellana C, Trujillo T, et al.
Transplantation . 2023 Oct; 107(11):e319. PMID: 37870884
No abstract available.
4.
Humoral Response After Five Successive Doses of SARS-CoV-2 mRNA Vaccine in Kidney Transplant Patients
Cazorla J, Villanego F, Aguilera A, Garcia T, Orellana C, Trujillo T, et al.
Transplantation . 2023 May; 107(7):e188-e189. PMID: 37170412
No abstract available.
5.
Real clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease
Naranjo J, Borrego F, Rocha J, Salgueira M, Martin-Gomez M, Orellana C, et al.
Front Med (Lausanne) . 2022 Oct; 9:987092. PMID: 36250074
Background: Tolvaptan (TV) is the first vasopressin-receptor antagonist approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD). No publications report TV experience in real clinical practice during the...
6.
Lipid profile of patients treated with evolocumab in Spanish hospital nephrology units (RETOSS NEFRO)
Goicoechea M, Alvarez V, Segarra A, Polaina M, Martin-Reyes G, Robles N, et al.
Nefrologia (Engl Ed) . 2022 Oct; 42(3):301-310. PMID: 36210619
Background And Objective: To describe the clinical characteristics, the reasons for initiating therapy and the effects of treatment in the initial phase of evolocumab availability in the Nephrology Units of...
7.
Trends in COVID-19 Outcomes in Kidney Transplant Recipients During the Period of Omicron Variant Predominance
Villanego F, Vigara L, Alonso M, Orellana C, Gomez A, Eady M, et al.
Transplantation . 2022 Apr; 106(6):e304-e305. PMID: 35389374
No abstract available.
8.
Effectiveness and safety of glucagon-like peptide-1 receptor agonist in a cohort of kidney transplant recipients
Vigara L, Villanego F, Orellana C, Naranjo J, Torrado J, Garcia T, et al.
Clin Transplant . 2022 Mar; 36(5):e14633. PMID: 35258121
No abstract available.
9.
[De novo IgA nephropathy in a kidney transplant recipient after SARS-CoV-2 vaccination]
Alonso M, Villanego F, Segurado O, Vigara L, Orellana C, Quiros P, et al.
Nefrologia . 2021 Dec; PMID: 34848906
No abstract available.
10.
Lipid profile of patients treated with evolocumab in Spanish hospital nephrology units (RETOSS NEFRO)
Goicoechea M, Alvarez V, Segarra A, Polaina M, Martin-Reyes G, Robles N, et al.
Nefrologia (Engl Ed) . 2021 Aug; PMID: 34389184
Background And Objective: To describe the clinical characteristics, the reasons for initiating therapy and the effects of treatment in the initial phase of evolocumab availability in the Nephrology Units of...